Spectrum Utilization and Congestion of IEEE 802.11 Networks in the 2.4 GHz ISM Band

Wi-Fi technology, plays a major role in society thanks to its widespread availability, ease of use and low cost. To assure its long term viability in terms of capacity and ability to share the spectrum efficiently, it is of paramount to study the spectrum utilization and congestion mechanisms in live environments. In this paper the service level in the 2.4 GHz ISM band is investigated with focus on todays IEEE 802.11 WLAN systems with support for the 802.11e extension. Here service level means the overall Quality of Service (QoS), i.e. can all devices fulfill their communication needs? A crosslayer approach is used, since the service level can be measured at several levels of the protocol stack. The focus is on monitoring at both the Physical (PHY) and the Medium Access Control (MAC) link layer simultaneously by performing respectively power measurements with a spectrum analyzer to assess spectrum utilization and packet sniffing to measure the congestion. Compared to traditional QoS analysis in 802.11 networks, packet sniffing allows to study the occurring congestion mechanisms more thoroughly. The monitoring is applied for the following two cases. First the influence of interference between WLAN networks sharing the same radio channel is investigated in a controlled environment. It turns out that retry rate, Clear-ToSend (CTS), Request-To-Send (RTS) and (Block) Acknowledgment (ACK) frames can be used to identify congestion, whereas the spectrum analyzer is employed to identify the source of interference. Secondly, live measurements are performed at three locations to identify this type of interference in real-live situations. Results show inefficient use of the wireless medium in certain scenarios, due to a large portion of management and control frames compared to data content frames (i.e. only 21% of the frames is identified as data frames)

Removing non-stationary noise in spectrum sensing using matrix factorization

Spectrum sensing is key to many applications like dynamicspectrum access (DSA) systems or telecom regulators who need to measure utilization of frequency bands. The International Telecommunication Union (ITU) recommends a 10 dB threshold above the noise to decide whether a channel is occupied or not. However, radio frequency (RF) receiver front-ends are non-ideal. This means that the obtained data is distorted with noise and imperfections from the analog front-end. As part of the front-end the automatic gain control (AGC) circuitry mainly affects the sensing performance as strong adjacent signals lift the noise level. To enhance the performance of spectrum sensing significantly we focus in this article on techniques to remove the noise caused by the AGC from the sensing data. In order to do this we have applied matrix factorization techniques, i.e., SVD (singular value decomposition) and NMF (non-negative matrix factorization), which enables signal space analysis. In addition, we use live measurement results to verify the performance and to remove the effects of the AGC from the sensing data using above mentioned techniques, i.e., applied on block-wise available spectrum data. In this article it is shown that the occupancy in the industrial, scientific and medical (ISM) band, obtained by using energy detection (ITU recommended threshold), can be an overestimation of spectrum usage by 60%

Effective Scheduling for Coded Distributed Storage in Wireless Sensor Networks

A distributed storage approach is proposed to access data reliably and to cope with node failures in wireless sensor networks. This approach is based on random linear network coding in combination with a scheduling algorithm based on backpressure. Upper bounds are provided on the maximum rate at which data can be reliably stored. Moreover, it is shown that the backpressure algorithm allows to operate the network in a decentralized fashion for any rate below this maximum

BRAF/MEK inhibitor rechallenge in advanced melanoma patients

Background: Effectivity of BRAF(/MEK) inhibitor rechallenge has been described in prior studies. However, structured data are largely lacking. Methods: Data from all advanced melanoma patients treated with BRAFi(/MEKi) rechallenge were retrieved from the Dutch Melanoma Treatment Registry. The authors analyzed objective response rate (ORR), progression-free survival (PFS), and overall survival (OS) for both first treatment and rechallenge. They performed a multivariable logistic regression and a multivariable Cox proportional hazards model to assess factors associated with response and survival. Results: The authors included 468 patients in the largest cohort to date who underwent at least two treatment episodes of BRAFi(/MEKi). Following rechallenge, ORR was 43%, median PFS was 4.6 months (95% confidence interval [CI], 4.1–5.2), and median OS was 8.2 months (95% CI, 7.2–9.4). Median PFS after rechallenge for patients who discontinued first BRAFi(/MEKi) treatment due to progression was 3.1 months (95% CI, 2.7–4.0) versus 5.2 months (95% CI, 4.5–5.9) for patients who discontinued treatment for other reasons. Discontinuing first treatment due to progression and lactate dehydrogenase (LDH) levels greater than two times the upper limit of normal were associated with lower odds of response and worse PFS and OS. Symptomatic brain metastases were associated with worse survival, whereas a longer treatment interval between first treatment and rechallenge was associated with better survival. Responding to the first BRAFi(/MEKi) treatment was not associated with response or survival. Conclusions: This study confirms that patients benefit from rechallenge. Elevated LDH levels, symptomatic brain metastases, and discontinuing first BRAFi(/MEKi) treatment due to progression are associated with less benefit from rechallenge. A prolonged treatment interval is associated with more benefit from rechallenge.</p

BRAF/MEK inhibitor rechallenge in advanced melanoma patients

Background: Effectivity of BRAF(/MEK) inhibitor rechallenge has been described in prior studies. However, structured data are largely lacking. Methods: Data from all advanced melanoma patients treated with BRAFi(/MEKi) rechallenge were retrieved from the Dutch Melanoma Treatment Registry. The authors analyzed objective response rate (ORR), progression-free survival (PFS), and overall survival (OS) for both first treatment and rechallenge. They performed a multivariable logistic regression and a multivariable Cox proportional hazards model to assess factors associated with response and survival. Results: The authors included 468 patients in the largest cohort to date who underwent at least two treatment episodes of BRAFi(/MEKi). Following rechallenge, ORR was 43%, median PFS was 4.6 months (95% confidence interval [CI], 4.1–5.2), and median OS was 8.2 months (95% CI, 7.2–9.4). Median PFS after rechallenge for patients who discontinued first BRAFi(/MEKi) treatment due to progression was 3.1 months (95% CI, 2.7–4.0) versus 5.2 months (95% CI, 4.5–5.9) for patients who discontinued treatment for other reasons. Discontinuing first treatment due to progression and lactate dehydrogenase (LDH) levels greater than two times the upper limit of normal were associated with lower odds of response and worse PFS and OS. Symptomatic brain metastases were associated with worse survival, whereas a longer treatment interval between first treatment and rechallenge was associated with better survival. Responding to the first BRAFi(/MEKi) treatment was not associated with response or survival. Conclusions: This study confirms that patients benefit from rechallenge. Elevated LDH levels, symptomatic brain metastases, and discontinuing first BRAFi(/MEKi) treatment due to progression are associated with less benefit from rechallenge. A prolonged treatment interval is associated with more benefit from rechallenge.</p

BRAF/MEK inhibitor rechallenge in advanced melanoma patients

BACKGROUND: Effectivity of BRAF(/MEK) inhibitor rechallenge has been described in prior studies. However, structured data are largely lacking. METHODS: Data from all advanced melanoma patients treated with BRAFi(/MEKi) rechallenge were retrieved from the Dutch Melanoma Treatment Registry. The authors analyzed objective response rate (ORR), progression-free survival (PFS), and overall survival (OS) for both first treatment and rechallenge. They performed a multivariable logistic regression and a multivariable Cox proportional hazards model to assess factors associated with response and survival. RESULTS: The authors included 468 patients in the largest cohort to date who underwent at least two treatment episodes of BRAFi(/MEKi). Following rechallenge, ORR was 43%, median PFS was 4.6 months (95% confidence interval [CI], 4.1-5.2), and median OS was 8.2 months (95% CI, 7.2-9.4). Median PFS after rechallenge for patients who discontinued first BRAFi(/MEKi) treatment due to progression was 3.1 months (95% CI, 2.7-4.0) versus 5.2 months (95% CI, 4.5-5.9) for patients who discontinued treatment for other reasons. Discontinuing first treatment due to progression and lactate dehydrogenase (LDH) levels greater than two times the upper limit of normal were associated with lower odds of response and worse PFS and OS. Symptomatic brain metastases were associated with worse survival, whereas a longer treatment interval between first treatment and rechallenge was associated with better survival. Responding to the first BRAFi(/MEKi) treatment was not associated with response or survival. CONCLUSIONS: This study confirms that patients benefit from rechallenge. Elevated LDH levels, symptomatic brain metastases, and discontinuing first BRAFi(/MEKi) treatment due to progression are associated with less benefit from rechallenge. A prolonged treatment interval is associated with more benefit from rechallenge

Improving survival in advanced melanoma patients: a trend analysis from 2013 to 2021

BACKGROUND: The prognosis of advanced melanoma patients has significantly improved over the years. We aimed to evaluate the survival per year of diagnosis. METHODS: All systemically treated patients diagnosed with advanced melanoma from 2013 to 2021 were included from the Dutch Melanoma Treatment Registry. Baseline characteristics and overall survival (OS) were compared between the different years of diagnosis. A multivariable Cox proportional hazards model was used to estimate the association between year of diagnosis and OS. FINDINGS: For this cohort study, we included 6260 systemically treated advanced melanoma patients. At baseline, there was an increase over the years in age, the percentage of patients with an ECOG PS ≥ 2, with brain metastases, and a synchronous diagnosis of primary and unresectable melanoma. Median OS increased from 11.2 months (95% CI 10.0-12.4) for patients diagnosed in 2013 to 32.0 months (95% CI 26.6-36.7) for patients diagnosed in 2019. Median OS was remarkably lower for patients diagnosed in 2020 (26.6 months; 95% CI 23.9-35.1) and 2021 (24.0 months; 95% CI 20.4-NR). Patients diagnosed in 2020 and 2021 had a higher hazard of death compared to patients diagnosed in 2019, although this was not significant. The multivariable Cox regression showed a lower hazard of death for the years of diagnosis after 2013. In contrast, patients diagnosed in 2020 and 2021 had a higher hazard of death compared to patients diagnosed in 2019. INTERPRETATION: After a continuous survival improvement for advanced melanoma patients between 2013 and 2019, outcomes of patients diagnosed in 2020 and 2021 seem poorer. This trend of decreased survival remained after correcting for known prognostic factors and previous neoadjuvant or adjuvant treatment, suggesting that it is explained by unmeasured factors, which-considering the timing-could be COVID-19-related. FUNDING: For the Dutch Melanoma Treatment Registry (DMTR), the Dutch Institute for Clinical Auditing foundation received a start-up grant from governmental organization The Netherlands Organization for Health Research and Development (ZonMW, project number 836002002). The DMTR is structurally funded by Bristol-Myers Squibb, Merck Sharpe & Dohme, Novartis, and Roche Pharma. Roche Pharma stopped funding in 2019, and Pierre Fabre started funding the DMTR in 2019. For this work, no funding was granted

A Survival Tree of Advanced Melanoma Patients with Brain Metastases Treated with Immune Checkpoint Inhibitors

The efficacy of immune checkpoint inhibitors (ICIs) in patients with advanced melanoma that develop brain metastases (BM) remains unpredictable. In this study, we aimed to identify prognostic factors in patients with melanoma BM who are treated with ICIs. Data from advanced melanoma patients with BM treated with ICIs in any line between 2013 and 2020 were obtained from the Dutch Melanoma Treatment Registry. Patients were included from the time of the treatment of BM with ICIs. Survival tree analysis was performed with clinicopathological parameters as potential classifiers and overall survival (OS) as the response variable. In total, 1278 patients were included. Most patients were treated with ipilimumab-nivolumab combination therapy (45%). The survival tree analysis resulted in 31 subgroups. The median OS ranged from 2.7 months to 35.7 months. The strongest clinical parameter associated with survival in advanced melanoma patients with BM was the serum lactate dehydrogenase (LDH) level. Patients with elevated LDH levels and symptomatic BM had the worst prognosis. The clinicopathological classifiers identified in this study can contribute to optimizing clinical studies and can aid doctors in giving an indication of the patients' survival based on their baseline and disease characteristics

Nitrogen losses from two grassland soils with different fungal biomass.

Nitrogen losses from agricultural grasslands cause eutrophication of ground- and surface water and contribute to global warming and atmospheric pollution. It is widely assumed that soils with a higher fungal biomass have lower N losses, but this relationship has never been experimentally confirmed. With the increased attention for soil-based ecosystem services and sustainable management of soils, such a relationship would be relevant for agricultural management. Here we present a first attempt to test this relationship experimentally . We used intact soil columns from two plots from a field experiment that had consistent differences in fungal biomass (68 ± 8 vs. 111 ± 9 μg C g-1) as a result of different fertilizer history (80 vs. 40 kg N ha-1 y-1 as farm yard manure), while other soil properties were very similar. In the greenhouse, the columns received either mineral fertilizer N or no N (control). We measured N leaching, N2O emissions and denitrification from the columns during 4 weeks, after which we analyzed fungal and bacterial biomass and soil N pools. We found that N2O emission and denitrification were lower in the high fungal biomass soil, irrespective of the addition of fertilizer N. After fertilizer addition, N leaching in low fungal biomass soil showed a 3-fold increase compared to the control (11.9 ± 1.0 and 3.9 ± 1.0 kg N ha-1, respectively), but did not increase in high fungal biomass soil (6.4 ± 0.9 after N addition vs. 4.5 ± 0.8 kg N ha-1 in the control). Thus, in the high fungal biomass soil more N was immobilized. An additional experiment with 15N–labelled mineral fertilizer, showed a 2-fold higher immobilization of 15N into microbial biomass in the high fungal biomass soil. However, only 3% of total 15N was found in the microbial biomass 2 weeks after the mineral fertilization. Most of the recovered 15N was in the plants (approximately 25%) or in the soil organic matter (approximately 15%). Our main experiment confirmed the assumption of lower N losses in a soil with higher fungal biomass. The additional 15N experiment showed that higher fungal biomass is probably not the direct cause of higher N immobilization, but rather the result of low nitrogen availability. Both experiments confirmed that higher fungal biomass can be considered as an indicator of higher nutrient retention in soils